key: cord-0912433-frp1gccq
authors: Chen, Wenyu; Yao, Ming; Hu, Lin; Zhang, Ye; Zhou, Qinghe; Ren, Hongwei; Sun, Yanbao; Zhang, Ming; Xu, Yufen
title: Development and validation of a clinical prediction model to estimate the risk of critical patients with COVID‐19
date: 2021-11-06
journal: J Med Virol
DOI: 10.1002/jmv.27428
sha: 93ce577fbbd09dd6e17e57b8f169b38d5a941884
doc_id: 912433
cord_uid: frp1gccq

The outbreak of coronavirus disease 2019 (COVID‐19) has globally strained medical resources and caused significant mortality. This study was aimed to develop and validate a prediction model based on clinical features to estimate the risk of patients with COVID‐19 at admission progressing to critical patients. Patients admitted to the hospital between January 16, 2020, and March 10, 2020, were retrospectively enrolled, and they were observed for at least 14 days after admission to determine whether they developed into severe pneumonia. According to the clinical symptoms, all patients were divided into four groups: mild, normal, severe, and critical. A total of 390 patients with COVID‐19 pneumonia were identified, including 212 severe patients and 178 nonsevere patients. The least absolute shrinkage and selection operator (LASSO) regression reduced the variables in the model to 6, which are age, number of comorbidities, computed tomography severity score, lymphocyte count, aspartate aminotransferase, and albumin. The area under curve of the model in the training set is 0.898, and the specificity and sensitivity were 89.7% and 75.5%. The prediction model, nomogram might be useful to access the onset of severe and critical illness among COVID‐19 patients at admission, which is instructive for clinical diagnosis.

A novel coronavirus was first discovered in Wuhan, China in December 2019, and has caused an unprecedented global health emergency. 1, 2 As of December 25, 2020, the World Health Organization (WHO) counted more than 79.39 million confirmed cases and more than 1.74 million deaths. 3 Most patients with coronavirus disease 2019 (COVID- 19) have mild clinical features, some even show no obvious symptoms at the time of infection, but then develop fatal complications, including severe pneumonia, acute respiratory distress syndrome, and multiple organ failure. 4 At present, there is no specific anti-coronavirus therapy for patients with severe symptoms, and the case fatality rate is about 20 times that of noncritically ill patients, which means the survival rate of these patients is very low. Treatment of these patients usually requires a large amount of medical resources. 5 Therefore, it has important clinical significance to identify severe patients with COVID-19 in the early.

The clinical classification of COVID-19 patients ranged from mild to severe, which is closely related to computed tomography (CT) findings. 6 A retrospective study showed that the probability of COVID-19 patients at admission developing severe disease ranged from 15.7% to 26.1%. These cases are usually associated with abnormal chest CT manifestations and clinical laboratory data. 7 Guan et al. 8 showed that patients with severe COVID-19

were more prone to ground-glass opacity (GGO), local or bilateral patchiness, and Interstitial lung abnormalities on CT, which can reflect the clinical progress of the disease, and also provide opportunities for the research of CT clinical utility, as the risk stratification of patients with a forecasting tool. In addition, CT has predictive value in the prognosis of patients with to ensure effective treatment and control the spread of disease.

Middle East respiratory syndrome (MERS) lead to poor prognosis. 9 CT has been suggested as an auxiliary method, used for screening individuals suspected of COVID-19 pneumonia during epidemics and monitoring treatment responses based on dynamic radiological changes. 10 

All patients enrolled met the following diagnostic criteria: highthroughput sequencing of nasal cavity and throat swab specimens or real-time reverse transcription polymerase chain reaction test results are positive. 1 Patients are observed for at least 14 days after admission to determine whether they develop into severe pneumonia.

According to the clinical symptoms, such as pneumonia, respiratory failure, shock, and other organ failures, all patients are divided into four groups: mild, normal, severe, and critical.

(1) Mild type, with mild clinical symptoms, and no pneumonia manifestations in imaging.

(2) Normal type, the patient has a fever, respiratory symptoms, and other symptoms, and pneumonia can be seen on imaging.

(3) Severe type, the patient has one of the following symptoms: (a) respiratory distress (respiratory rate ≥30 breaths/min);

(b) hypoxia (oxygen saturation ≤93% in a resting state); (c) low oxyemia (arterial blood oxygen partial pressure/inspired oxygen concentration ≤300 mmHg). In this study, no mild patients and no patients developed into critical illness, so all patients were divided into severe and nonsevere cases.

The professional clinical team reviews, extracts, and cross-checks the data, and two clinicians check the recorded results independently.

The data extracted from the electronic medical records are as follows: demographic information (age, gender), contact history (defined as a contact in Wuhan within two weeks before the onset of the disease, or contact with local residents diagnosed with SARS-CoV-2 infection), smoking history, comorbidities (mainly including diabetes, hypertension, cardiovascular disease, COPD, malignant tumors, and chronic liver disease, scored according to the number of comorbidities, the maximum is not more than 5 points if there is no score, 0 points), clinical symptoms and signs include categorical and continuous variables: body temperature at admission, the main symptoms include fever, cough/sputum, hemoptysis, chest tightness/shortness of breath, other symptoms include fatigue, loss of appetite, dyspnea, malaise, diarrhea, headache, and so forth (score based on the number of symptoms, up to 7 points). Laboratory examination results are as follows: blood routine indicators include platelet, white blood cell, neutrophil, lymphocyte, hematocrit, monocyte, eosinophil, hemoglobin, and red blood cell. Biochemical indicators include alanine aminotransferase, aspartate aminotransferase, albumin, creatinine, serum sodium, serum potassium, and C-reactive protein. Blood gas analysis includes PaO 2 , PaCO 2 , and pH. In addition, erythrocyte sedimentation rate, fibrinogen, procalcitonin, and length of hospital stay were also recorded. The imaging findings include abnormalities in CT and its severity.

In this study, two radiologists with more than 10 years of experience in chest imaging conducted an independent review of all CT images.

When the two radiologists diverged in interpreting the imaging results, a third experienced radiologist gave his opinion. The CT recorded imaging features included GGO, pulmonary consolidation, crazy paving, and air bronchogram. 15, 16 GGO is defined as lung blur aggravating attenuation and preservation of bronchi and blood vessel edges, while lung consolidation is defined as blurring and opacity of blood vessel edges and airway walls. Crazy paving refers to the thickening of the lobular septum and the appearance of thickened ground glass in the interlobular septum.

The distribution pattern of the lesions and the involvement of the lobes and segments were also evaluated. The CT appearance of the outer third of the lung is defined as the periphery, and the CT appearance of twothirds of the lung is defined as the center. In addition, the presence of discrete nodules, swollen lymph nodes, and pleural effusion was also recorded. 17 Each of the five lung lobes was examined, and the degree of lesions in each lobe was evaluated semiquantitatively from 0 to 5 according to the degree of involvement: score 0, no participation; score 1, participation ≤5%; Score 2, participation rate 6%-25%; score 3, participation rate 26%-50%; score 4, participation 51%-75%; score 5, participation rate >75%. 16 The total score is obtained by summing the scores of all five leaves to provide a CT severity score between 0 and 25.

Use least absolute shrinkage and selection operator (LASSO) regression analysis to filter the variables we need. Using the R "caret" package, 390 patients were randomly divided into training sets and validation sets at a ratio of 1:1. Apply LASSO regression to minimize the potential collinearity between different variables and variable overfitting. If the missing value is <20%, consider filling in the missing variable. We use predictive mean matching to estimate numerical features, logistic regression to estimate binary variables, and Bayesian polymorphic regression to estimate factor features. We use L1 minimized LASSO regression for multivariate analysis, and use 10-fold cross-validation for internal validation. This is a logistic regression model, which penalizes the absolute size of the regression model's coefficients based on the value of λ.

When the penalty is greater, the estimate of the weaker factor will approach zero, so only the strongest predictor variable remains in the model. The best variable is selected by the smallest λ value. The R software package "glmnet" statistical software (R Foundation) was used to perform LASSO regression. Subsequently, the variables determined by the LASSO regression analysis were subjected to logistic regression analysis to construct our risk prediction model. 

A total of 32 independent variables were collected from the original data, and 11 insignificant factors were eliminated through the nonparametric rank-sum test. We used 1:1 nonrepetitive random sampling on the original data and divided it into a training set and a validation set (Figure 1 ). The remaining 21 independent variables were used for LASSO regression analysis. Finally, six independent variables were selected for multivariate logistic regression analysis (Figure 2 ). The results showed that age, number of comorbidities, CT severity score, lymphocyte count, aspartate aminotransferase, and albumin are risk factors for the progression of COVID-19 disease ( Table 2 ). The constructed nomogram of COVID-19 disease progression risk prediction is shown in (Table 3 ).

The ROC curve shows the accuracy of the nomogram for COVID- 20 On the other hand, a large number of studies currently analyze the clinical data of patients with COVID-19 pneumonia, which can predict the patient's disease progression and take targeted treatment measures to effectively prevent further aggravation of the disease. Age is the most common factor affecting disease progression. Previously, older age was reported as an important independent predictor of mortality from severe acute respiratory syndrome (SARS) and MERS, which is also applicable in COVID-19. 21-23 A recent retrospective study showed that older age, comorbidities, and severe CT scores are risk factors for COVID-19 severe/critical pneumonia. 24 Another factor that is more closely related to it is comorbidities. It is not difficult to explain that the physical fitness of the elderly is significantly reduced, and they are more likely to suffer from multiple complications. Different from the underlying disease, a large cohort study suggested that cancer patients are more likely to be infected with SARS-CoV-2 and are prone to develop severe pneumonia, and the results showed that chest CT can quickly and accurately assess the severity of COVID-19 pneumonia, especially for critical cases. 29 A large amount of evidence shows that CT imaging provides an important reference for the early diagnosis and treatment of patients with COVID-19 pneumonia. 30 With reference to the previous experience of MERS and SARS, the imaging results will help us better judge the disease progression of patients with COVID-19 pneumonia. 31 It is worth noting that a study reported that the total severity score of CT has high diagnostic performance in evaluating severe and general patients, but it is not suitable as an independent diagnostic factor, which is different from clinical patients. The distribution ratio of 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

A facile approach to enhance antigen response for personalized cancer vaccination

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changes

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Clinical characteristics of coronavirus disease 2019 in China

CT correlation with outcomes in 15 patients with acute Middle East respiratory syndrome coronavirus

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Development of a clinical decision support system for severity risk prediction and triage of COVID-19 patients at hospital admission: an international multicentre study

Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19

A novel simple scoring model for predicting severity of patients with SARS-CoV-2 infection

Reporting and interpreting decision curve analysis: a guide for investigators

Radiographic and CT features of viral pneumonia

CT imaging features of 2019 novel coronavirus (2019-nCoV)

Fleischner Society: glossary of terms for thoracic imaging

Multicenter development and validation of a novel risk nomogram for early prediction of severe 2019-novel coronavirus pneumonia

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2

China novel coronavirus investigating and research team. a novel coronavirus from patients with pneumonia in China

Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong

Predictors of mortality in Middle East respiratory syndrome (MERS)

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

The clinical and chest CT features associated with severe and critical COVID-19 pneumonia

Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak

Development and validation of a prognostic model based on comorbidities to predict COVID-19 severity: a population-based study

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

The performance of chest CT in evaluating the clinical severity of COVID-19 pneumonia: identifying critical cases based on CT characteristics

Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2

Radiology perspective of coronavirus disease 2019 (COVID-19): lessons from severe acute respiratory syndrome and Middle East respiratory syndrome

CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19)

Development and validation of a clinical prediction model to estimate the risk of critical patients with COVID-19

The authors declare that there are no conflict of interests.

Wenyu Chen and Yufen Xu had full access to all of the data in the study and take responsibility for the integrity of the data and the 

The data analyzed during the current study are available from the corresponding author on reasonable request.

This study was approved by the Medical Ethics Committee of Jiaxing First Hospital (LS2020-009). All the patients were provided with written informed consent before enrollment.

http://orcid.org/0000-0003-0412-2913